Caris Life Sciences heads into its third-quarter report with an unusual setup. The stock has rallied about 71% since its last report, but Wall Street's quarterly forecast still looks cautious next to what management told investors in August. Consensus calls for revenue of $250.9 million, roughly $13 million below the $263.7 million Caris posted in the second quarter. That forecast implies a sequential step back for a company that just raised its full-year outlook on accelerating test volumes.

The numbers reflect two different stories. Revenue is expected to grow 15.7% from a year ago, which is solid but well short of the 27% to 28% full-year growth management now targets. Earnings per share are projected at $0.03, down from $0.08 a year earlier, a 62.5% decline. Heavier spending on new product launches explains much of that drop. Management lifted its 2026 revenue range to $1.03 billion to $1.04 billion from $1.00 billion to $1.02 billion. The full-year consensus of about $989 million sits below even the low end of that range. Either analysts doubt the guidance or their models have not caught up. Revenue anywhere near the second-quarter level would suggest the Street has been too conservative.

The August call marked a turn from a choppy first quarter. Early in the year, Caris nearly doubled its sales territories from 82 to 146, and the realignment disrupted volumes for a time. By the second quarter, clinical cases hit a record 59,200, up 18% from a year earlier and 12% from the first quarter. Tissue testing re-accelerated, blood-based Caris Assure cases rose 50%, and average selling prices topped $3,850. GAAP gross margin widened to 68% from 65% in the first quarter. The key test now is whether that sales-force payoff holds up. Another sequential volume gain, rather than a plateau after one strong quarter, would confirm that the territory expansion is a lasting driver.

Margins carry their own tension. Caris Detect, the multi-cancer early detection test launched in June, and the ChromaSeq assay both start at lower gross margins. Management also raised its operating expense outlook to $595 million to $600 million and expected third-quarter capital spending of $15 million to $20 million to support Detect. Gross margin that holds near 68% while Detect ramps would be an encouraging sign. A sharp slip would raise doubts about how quickly the new products can scale profitably. Free cash flow was expected to be roughly breakeven over the first nine months, so another inventory build is not alarming by itself. A clear miss on that target would be.

Detect is the wild card. Its contribution is excluded from guidance, yet management described a plan to triple capacity toward about $3 billion in annual revenue potential, with a direct-to-consumer ad campaign due around now. Any early read on order trends, backlog, or capacity strain would matter more than the quarter's headline earnings. So would progress on the planned MRD launch, MyClarity V2, New York approval for Assure, and the soft pharma services line, which brought in just $11.4 million last quarter.

Sentiment has swung from clearly bearish before the last report to mildly bullish now. At $32.46, the stock sits far above its 200-day moving average of $21.45 and within about 1% of its post-earnings high of $32.89, so it is testing a breakout. That leaves little room for a stumble. The central question is whether clinical volume and pricing keep compounding while Detect spending rises. If they do, the raised guidance looks conservative and the Street's numbers move higher. If volume stalls, the rally may have run ahead of the fundamentals.